$BBIO

$69.37 +$1.22 (1.79%) Close

$BBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 195.5M shares outstanding

Who owns BBIO?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 60.5%

Cormorant Asset Management, LP 9.4% · BlackRock, Inc. 6.4%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

485

+1 vs last qtr

Net shares bought

−283.4K

by institutions in Q2 2026

New / sold out

79 / 78

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +14.1M
Wellington Management Group LLP +2.8M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −13.2M
BlackRock, Inc. −3.9M

Who is planning to sell?

Notices of proposed sale, last 12 months

$97.1M

31 notices from 12 people

Shares covered

1.3M

0.68% of the company

Arranged in advance

88%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Jennifer Cook Director 10b5-1 $21.9M
Kumar Haldea Revocable Trust U/a DTD 12/19/2018 Director 10b5-1 $17.8M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+62.3%

+10.17% a year

Each share's claim on the business

−38.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

$323M vs $587M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years53% 3–5 years7% 1–3 years19% Under 1 year22%

Quarterly turnover

18.1%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting BBIO on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
CA Cormorant Asset Management, LP	18.4M	9.43%	−300.0K (−1.6%)	≤2021	9.1%
Shares held by quarter Peak holding19.3M (Q3'25) Change over 8 quarters+16.6M Share of the company9.430% Cormorant Asset Management, LP's full portfolio →
B BlackRock, Inc.	12.4M	6.36%	−3.9M (−23.7%)	≤2021	0.0%
Shares held by quarter Peak holding16.6M (Q4'25) Change over 8 quarters−438.3K Share of the company6.360% BlackRock, Inc.'s full portfolio →

Cormorant Asset Management, LP

18.4M

% of company

9.43%

Change vs last qtr

−300.0K (−1.6%)

Held since

≤2021

BlackRock, Inc.

12.4M

% of company

6.36%

Change vs last qtr

−3.9M (−23.7%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding BridgeBio Pharma, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting BBIO on Form N-PORT; together they hold 41.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$428M	7.0M	3.59%	0.02%	June 30, 2026
VS Vanguard Small-Cap Index Fund Vanguard Index Funds	$301M	4.0M	2.07%	0.16%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$428M

% of company

3.59%

% of the fund

0.02%

As of

June 30, 2026

Vanguard Small-Cap Index Fund

Vanguard Index Funds

Position value

$301M

% of company

2.07%

% of the fund

0.16%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding BridgeBio Pharma, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
SR Shabet Rose Sharon 5%+ holder 13D · 5.0%	9.8M	5.01%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company5.010% Disclosed stake13D · 5.0% View the 13D/G filing →
HO Halvorsen Ole Andreas 5%+ holder 13D · 5.0%	9.8M	5.01%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company5.010% Disclosed stake13D · 5.0% View the 13D/G filing →

Shabet Rose Sharon

5%+ holder13D · 5.0%

9.8M

% of company

5.01%

Change vs last qtr

—

Held since

—

Halvorsen Ole Andreas

5%+ holder13D · 5.0%

9.8M

% of company

5.01%

Change vs last qtr

—

Held since

—

22 more holders behind a free account

See every insider and 5%+ holder of BridgeBio Pharma, Inc..

Comments